Table 1.
Demographic features and organ involvements of SLE patients
| Variables | All patients (n = 125) |
|---|---|
| Age (years), median (range) | 36.0 (13.0–81.0) |
| Female | 116 (92.8) |
| Disease duration (months), median (range) | 24.0 (0.1–360.0) |
| Treated patients | 76 (60.8) |
| ESR (mm/H), median (range) | 28.0 (2.0–142.0) |
| CRP (mg/l), median (range) | 5.4 (0.2–139.8) |
| C3 (g/l), median (range) | 0.520 (0.060–1.120) |
| C4 (g/l),median (range) | 0.100 (0.017–0.389) |
| Hypocompleminemia | 103 (82.4) |
| Fever | 17 (8.0) |
| Rash | 43 (34.4) |
| Alopecia | 18 (14.4) |
| Oral ulcers | 7 (5.6) |
| Pleurisy | 14 (11.2) |
| Pericarditis | 12 (9.6) |
| Joint involvement | 34 (27.2) |
| Myositis | 5 (4.0) |
| Vasculitis | 10 (8.0) |
| Renal involvement | 68 (54.4) |
| Albuminuria | 37 (29.6) |
| Hematuria | 40 (32.0) |
| Leukocyturia | 45 (36.0) |
| Cylindruria | 12 (9.6) |
| Neurologic involvement | 6 (4.8) |
| Leukopenia | 50 (40.0) |
| Leukocyte count (109/l), median (range) | 4.0 (1.3–12.5) |
| Neutropenia | 26 (20.8) |
| Neutrophil count (109/l), median (range) | 2.5 (0.5–9.5) |
| Lymphopenia | 69 (55.2) |
| Lymphocyte count (109/l), median (range) | 0.9 (0.2–3.6) |
| Anemia | 73 (58.4) |
| Hemoglobin (g/l), mean ± SD | 109.1 ± 22.6 |
| Thrombocytopenia | 41 (32.8) |
| Platelet count (109/l), mean ± SD | 167.6 ± 91.2 |
| Anti-dsDNA | 89 (71.2) |
| Anti-Smith | 34 (27.2) |
| Anti-U1RNP | 65 (52.0) |
| Anti-ribosomal P protein | 31 (24.8) |
| Anti-Ro60 | 74 (59.2) |
| Anti-Ro52 | 64 (51.2) |
| Anti-SSB | 16 (12.8) |
| Anti-centromere protein B | 9 (7.2) |
| Anti-phospholipid | 30 (24.0) |
| Direct Coombs’ test | 16 (12.8) |
| SLEDAI 2000 score | 11.0 (0–39.0) |
Except where indicated otherwise, values are n (%)
anti-dsDNA anti-double stranded DNA, C3 complement 3, C4 complement 4, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SLE systemic lupus erythematosus, SLEDAI 2000 systemic lupus erythematosus disease activity index 2000